Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. “These data support the potential of our transdermal [through-the-skin] platform as a…
News
Higher TAGLN2 gene activity may contribute to the development of pulmonary arterial hypertension (PAH), according to a new study. Using genetic analyses and experiments in animals, researchers identified two specific DNA sites that influenced TAGLN2 expression (activity) and PAH risk. These are two sites where a chemical mark called…
Risk factors for pulmonary hypertension (PH) in people receiving maintenance hemodialysis, a blood-filtering treatment used when kidney function is severely reduced, appear to change with age, according to a single-center study in China. Diabetes was a risk factor for PH in patients 60 or older. In younger patients, PH…
Note: This story was updated May 28, 2026, to clarify the indications for which Cereno Scientific’s experimental therapies are being developed. The company is advancing CS1 as a potential treatment for pulmonary arterial hypertension. The first participant has been dosed in a clinical trial testing the pharmacological properties of…
An experimental inhaled therapy called LAM-001 significantly reduced symptom severity for all patients who completed a small Phase 2a clinical trial for pulmonary hypertension with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension. “These findings are encouraging for patients and the broader pulmonary hypertension community and support continued development…
Using artificial intelligence (AI) analyses of clinical data from hundreds of patients, scientists have created a new system to calculate the risk of future clinical worsening in people with pulmonary arterial hypertension (PAH). “To our knowledge, this is the first study to use machine learning to leverage existing [electronic…
Using artificial intelligence (AI) and analyzing genetic data focused on two primary biochemical processes, a team of scientists in China has identified two genes that appear to play key roles in driving pulmonary arterial hypertension (PAH). Computer-based analyses suggest that these two genes, called ATP1B1 and HP, may be…
A new partnership aims to incorporate more patient perspectives into the development of medications for pulmonary hypertension (PH). Cereno Scientific will partner with PHA Europe & Global on a patient-centered drug design project. Patient-centered drug development enables people affected by a disease to contribute throughout the development…
Top-line results from a Phase 2 trial of TX45, Tectonic Therapeutics’ experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), are expected late this year or early next year, the company said. The trial, APEX…
Mannkind said it is creating an inhaled formulation of ralinepag, an experimental oral pulmonary arterial hypertension (PAH) treatment, for developer United Therapeutics. The inhaled version, ralinepag DPI, will be a dry powder that delivers the drug directly to the lungs, providing an alternative to the tablet formulation. The…
Treatment with treprostinil, a medicine that relaxes blood vessels, led to significant and sustained improvements in children with pulmonary hypertension (PH) caused by different lung conditions, according to a retrospective analysis. Findings from the analysis were detailed in the study, “Treprostinil Is Associated With Early and Sustained Improvement…
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
